Answers are grounded in this paper and cite their sources.
(1) Background: Improving the survival rate of neonatal piglets by boosting their hepatic function and morphology is a key priority for swine producers. This study was designed to evaluate the effects of maternal supplementation with ATRA on the liver of neonatal piglets. (2) Methods: Fifteen pregnant sows were randomly assigned to five ATRA treatment groups, including ATRA-0 (0 mg ATRA/kg diet), ATRA-4 (4 mg ATRA/kg diet), ATRA-8 (8 mg ATRA/kg diet), ATRA-16 (16 mg ATRA/kg diet) and ATRA-32 (32 mg ATRA/kg diet); each group had three sows. ATRA were administered to sows from day 12 to day 95 of gestation. Prior to suckling, one male and one female neonatal piglet were chosen from each litter for the collection of liver and bile samples, which were then subjected to analysis by histology, UHPLC-MS/MS, and RNA-seq. (3) Results: Compared with piglets in the ATRA-0 group, those from the ATRA-4 treatment exhibited an increased (p < 0.05) percentage of bile duct epithelial cells, upregulated (p < 0.05) expression of IGF1, PPP1R3E, FOXO1, PCK1, ACOX3 and ABCG1, downregulated (p < 0.05) expression of PPARA, IL1R2 and IL1RAP, higher (p < 0.05) isolithocholic acid concentration and lower (p < 0.05) ursodeoxycholic acid-3-sulfate concentration in the liver. (4) Conclusions: Supplementing sow with 4 mg ATRA/kg diet during gestation can promote hepatic development and function in neonatal piglets. This beneficial effect is achieved by increasing the percentage of bile duct epithelial cells, upregulating the expression of genes related to glycogen synthesis, gluconeogenesis and fatty acid β-oxidation, and elevating some secondary bile acid concentrations.
No takes yet. Share an insight, caveat, or question.
Wen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: